At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) phase 2 BELIEF clinical trial, which evaluated erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without the T790M mutation.
BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer
9th December 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now